Eli Lilly’s anti-obesity drug could surpass Ozempic
The American pharmaceutical company has revised its forecasts above and now expects annual sales between $45.4 and $46.6 billion, or $3 billion more than previously expected. This is the second time this year that the group has reviewed its forecasts. As the stock market opened, shares rose 14% before slowing to 7.5% during the day. … Read more